Kopitar Z
Arzneimittelforschung. 1975 Sep;25(9):1455-60.
Investigations of pharmacokinetics and metabolism of 14C-labelled 1-cyclohexyl-3 (p-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2-(1H)-isoquinolyl)-ethyl]-phenyl)-sulfonyl)-urea (AR-DF 26; gliquidone; Glurenorm) after i.v. and oral applications were carried out on 10 healthy volunteers. After oral application of 15 mg AR-DF 26, maximum blood levels of 370 ng/ml blood or 700 ng/ml plasma, respectively, were reached. After i.v. as well as oral application of AR-DF 26 in men the bulk of the substance applied was excreted with the faeces and only 5 percent were found in urine. After both modes of application the metabolites in the faeces were found to be quantitatively and qualitatively similar. The structure of 4 metabilites was demonstrated by isotope dilution analysis.
对10名健康志愿者进行了静脉注射和口服14C标记的1-环己基-3(对-[2-(3,4-二氢-7-甲氧基-4,4-二甲基-1,3-二氧代-2-(1H)-异喹啉基)-乙基]-苯基)-磺酰基)-脲(AR-DF 26;格列喹酮;糖适平)后的药代动力学和代谢研究。口服15mg AR-DF 26后,分别达到了370ng/ml血液或700ng/ml血浆的最大血药浓度。在男性中静脉注射和口服AR-DF 26后,大部分给药物质随粪便排出,仅5%在尿液中发现。两种给药方式后,粪便中的代谢产物在数量和质量上均相似。通过同位素稀释分析确定了4种代谢产物的结构。